PHARVARIS NV (PHVS)

NL00150005Y4 - Common Stock

19.96  -1.29 (-6.07%)

Fundamental Rating

2

Overall PHVS gets a fundamental rating of 2 out of 10. We evaluated PHVS against 198 industry peers in the Pharmaceuticals industry. While PHVS seems to be doing ok healthwise, there are quite some concerns on its profitability. PHVS does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

PHVS had negative earnings in the past year.
PHVS had a negative operating cash flow in the past year.
In the past 5 years PHVS always reported negative net income.
In the past 5 years PHVS always reported negative operating cash flow.

1.2 Ratios

PHVS has a Return On Assets of -63.38%. This is in the lower half of the industry: PHVS underperforms 64.62% of its industry peers.
The Return On Equity of PHVS (-70.09%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.38%
ROE -70.09%
ROIC N/A
ROA(3y)-30.46%
ROA(5y)-42.03%
ROE(3y)-33.03%
ROE(5y)-45.65%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

PHVS has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, PHVS has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 37.17 indicates that PHVS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 37.17, PHVS belongs to the top of the industry, outperforming 97.44% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that PHVS is not too dependend on debt financing.
PHVS has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 37.17
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

PHVS has a Current Ratio of 10.48. This indicates that PHVS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.48, PHVS belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
PHVS has a Quick Ratio of 10.48. This indicates that PHVS is financially healthy and has no problem in meeting its short term obligations.
PHVS has a better Quick ratio (10.48) than 87.69% of its industry peers.
Industry RankSector Rank
Current Ratio 10.48
Quick Ratio 10.48

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PHVS have decreased strongly by -154.17% in the last year.
EPS 1Y (TTM)-154.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-132%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 9.01% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.88%
EPS Next 2Y3.55%
EPS Next 3Y-3.93%
EPS Next 5Y9.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PHVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PHVS's earnings are expected to decrease with -3.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.55%
EPS Next 3Y-3.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARVARIS NV

NASDAQ:PHVS (4/25/2024, 10:58:36 AM)

19.96

-1.29 (-6.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.07B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.38%
ROE -70.09%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 10.48
Quick Ratio 10.48
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-154.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y